Skip to main content
Premium Trial:

Request an Annual Quote

European Union Extends Review of Agilent, Varian Deal

NEW YORK (GenomeWeb News) – European Union regulators have extended their review deadline to Jan. 20 from the previous Jan. 6 on the proposed acquisition of Varian by Agilent Technologies.

According to a Reuters report today, EU regulators extended the deadline to make a decision on the deal after Agilent agreed to remedies for competition concerns. Those remedies were not specified, and Agilent officials did not return a call seeking comment before this article was published.

Agilent had reached an agreement in July to acquire Varian for around $1.5 billion. The firms said at the time that they expected to close the deal before the end of this year.

In September, the US Federal Trade Commission asked Varian and Agilent for additional information in connection with the proposed merger.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.